Trial reportPloS one2010
Motion sickness, stress and the endocannabinoid system.
Trial report in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 139 citations in OpenAlex.
- Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome.Neurogastroenterology and motility · 2019Pooled it
- Pooled it
- Psychological and endocannabinoid responses to aerobic exercise in substance use disorder patients.Substance abuse · 2021Trial
- Examining potential effects of arousal, valence, and likability of music on visually induced motion sickness.Experimental brain research · 2020Trial
- Novel associations between FAAH genetic variants and postoperative central opioid-related adverse effects.The pharmacogenomics journal · 2015Trial
- Endocannabinoids and related lipids in blood plasma following touch massage: a randomised, crossover study.BMC research notes · 2015Trial
- Trial
- Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Trial
- Endocannabinoid response to social stress in chronic non-medical prescription opioid users.Psychopharmacology · 2026Article
- Relationships among peri-traumatic circulating endocannabinoids and long-term, negative outcomes following traumatic injury.Psychopharmacology · 2026Article
- The Role of Cannabinoids and the Endocannabinoid System in the Treatment and Regulation of Nausea and Vomiting.Current topics in behavioral neurosciences · 2026Review
- Spaceflight exposome/microgravity effects on the psychoimmunoneuroendocrine system.NPJ microgravity · 2025Review
- Insulin level regulators may affect cognitive ability caused by motion sickness: an experimental study.Metabolic brain disease · 2025Article
- Biological sex as a variable in immunity does not affect parabolic flight-induced alterations in immune responses.Frontiers in immunology · 2025Article
- Treats containing cannabidiol, L-tryptophan andFrontiers in veterinary science · 2025Article
- Cellular and Molecular Effects of Microgravity on the Immune System: A Focus on Bioactive Lipids.Biomolecules · 2024Review
- Study of Motion Sickness Model Based on fNIRS Multiband Features during Car Rides.Diagnostics (Basel, Switzerland) · 2023Article
- Nutritional and Behavioral Countermeasures as Medication Approaches to Relieve Motion Sickness: A Comprehensive Review.Nutrients · 2023Review
- A review of the auditory-gut-brain axis.Frontiers in neuroscience · 2023Review
- Cannabidiol Interferes with Establishment of ΔCannabis and cannabinoid research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA substantial number of individuals are at risk for the development of motion sickness induced nausea and vomiting (N&V) during road, air or sea travel. Motion sickness can be extremely stressful but the neurobiologic mechanisms leading to motion sickness are not clear. The endocannabinoid system (ECS) represents an important neuromodulator of stress and N&V. Inhibitory effects of the ECS on N&V are mediated by endocannabinoid-receptor activation. METHODOLOGY/PRINCIPAL
findingsWe studied the activity of the ECS in human volunteers (n = 21) during parabolic flight maneuvers (PFs). During PFs, microgravity conditions (<10(-2) g) are generated for approximately 22 s which results in a profound kinetic stimulus. Blood endocannabinoids (anandamide and 2-arachidonoylglycerol, 2-AG) were measured from blood samples taken in-flight before start of the parabolic maneuvers, after 10, 20, and 30 parabolas, in-flight after termination of PFs and 24 h later. Volunteers who developed acute motion sickness (n = 7) showed significantly higher stress scores but lower endocannabinoid levels during PFs. After 20 parabolas, blood anandamide levels had dropped significantly in volunteers with motion sickness (from 0.39+/-0.40 to 0.22+/-0.25 ng/ml) but increased in participants without the condition (from 0.43+/-0.23 to 0.60+/-0.38 ng/ml) resulting in significantly higher anandamide levels in participants without motion sickness (p = 0.02). 2-AG levels in individuals with motion sickness were low and almost unchanged throughout the experiment but showed a robust increase in participants without motion sickness. Cannabinoid-receptor 1 (CB1) but not cannabinoid-receptor 2 (CB2) mRNA expression in leucocytes 4 h after the experiment was significantly lower in volunteers with motion sickness than in participants without N&V. CONCLUSIONS/SIGNIFICANCE: These findings demonstrate that stress and motion sickness in humans are associated with impaired endocannabinoid activity. Enhancing ECS signaling may represent an alternative therapeutic strategy for motion sickness in individuals who do not respond to currently available treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.